GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (LTS:0HUZ) » Definitions » Cyclically Adjusted Book per Share

Imunon (LTS:0HUZ) Cyclically Adjusted Book per Share : $64.78 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Imunon Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Imunon's adjusted book value per share for the three months ended in Sep. 2024 was $0.565. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $64.78 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Imunon's average Cyclically Adjusted Book Growth Rate was -47.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -21.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -17.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -20.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Imunon was -0.30% per year. The lowest was -35.10% per year. And the median was -8.90% per year.

As of today (2025-01-19), Imunon's current stock price is $0.90. Imunon's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was $64.78. Imunon's Cyclically Adjusted PB Ratio of today is 0.01.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Imunon was 0.80. The lowest was 0.01. And the median was 0.07.


Imunon Cyclically Adjusted Book per Share Historical Data

The historical data trend for Imunon's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Cyclically Adjusted Book per Share Chart

Imunon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 228.62 234.19 224.60 171.09 114.85

Imunon Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 116.18 114.85 101.70 70.79 64.78

Competitive Comparison of Imunon's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Imunon's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Imunon's Cyclically Adjusted PB Ratio falls into.



Imunon Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Imunon's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book= Book Value per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.565/133.0289*133.0289
=0.565

Current CPI (Sep. 2024) = 133.0289.

Imunon Quarterly Data

Book Value per Share CPI Adj_Book
201412 344.945 99.070 463.186
201503 280.445 99.621 374.492
201506 265.678 100.684 351.028
201509 228.734 100.392 303.096
201512 183.591 99.792 244.737
201603 137.239 100.470 181.713
201606 134.506 101.688 175.961
201609 85.189 101.861 111.256
201612 45.238 101.863 59.079
201703 23.117 102.862 29.897
201706 16.864 103.349 21.707
201709 9.492 104.136 12.126
201712 23.185 104.011 29.653
201803 19.963 105.290 25.222
201806 16.185 106.317 20.251
201809 12.672 106.507 15.828
201812 16.616 105.998 20.853
201903 16.323 107.251 20.246
201906 13.450 108.070 16.556
201909 10.540 108.329 12.943
201912 9.390 108.420 11.521
202003 8.310 108.902 10.151
202006 10.928 108.767 13.366
202009 7.740 109.815 9.376
202012 6.859 109.897 8.303
202103 10.989 111.754 13.081
202106 11.100 114.631 12.881
202109 10.283 115.734 11.820
202112 9.669 117.630 10.935
202203 8.018 121.301 8.793
202206 6.627 125.017 7.052
202209 5.825 125.227 6.188
202212 3.944 125.222 4.190
202303 2.929 127.348 3.060
202306 2.325 128.729 2.403
202309 1.929 129.860 1.976
202312 1.424 129.419 1.464
202403 0.904 131.776 0.913
202406 0.398 132.554 0.399
202409 0.565 133.029 0.565

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Imunon  (LTS:0HUZ) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Imunon's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.90/64.78
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Imunon was 0.80. The lowest was 0.01. And the median was 0.07.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Imunon Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Imunon's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Imunon Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (LTS:0HUZ) » Definitions » Cyclically Adjusted Book per Share
Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

Imunon Headlines

No Headlines